BioSpace News Archive

Jemincare announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration and 2 approvals from the U.S. Food & Drug Administration.

Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors.

Inspira Technologies OXY BHN Ltd., a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, announced a significant advancement in its sensor technology by its team of experts.

Nectin Therapeutics Ltd. announced that it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug KEYTRUDA®, MSD’s anti-PD-1 therapy, and expanded the trial to four additional global sites to include Sheba Medical Center, Hadassah Medical Center, Ochsner Health, and City of Hope along with flagship site, MD Anderson Cancer Center.

Madryn Asset Management, LP, a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc., disclosed that the Transaction Committee of the Company’s Board of Directors did not pursue a substantive dialogue with Laboratory Corporation of America Holdings – one of the industry’s most logical strategics, with a $19 billion market capitalization – before recommending shareholders vote for the proposed merger with Standard BioTools Inc.

Ainos, Inc. announced that it is initiating the second phase of co-development of a volatile organic compound sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co.

RetinalGeniX™ Technologies Inc., announced that it has contracted with MEDsan, Inc. to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on October 30, 2023.

SomaLogic, Inc., a leader in proteomics technology, issued the following statement in response to a press release issued by Madryn Asset Management, LP on December 26, 2023, regarding the pending merger with Standard BioTools.

PharmaBlock Sciences, Inc., a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API GMP facility at its Zhejiang manufacturing site.

Everest Medicines announced that its New Drug Application for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration for the treatment of primary immunoglobulin A nephropathy in adult patients.